Chondroitin sulfate proteoglycans (CSPGs) are the main component of the extracellular matrix in the central nervous system (CNS) and influence neuroplasticity. Although CSPG is considered an inhibitory factor for nerve repair in spinal cord injury, it is unclear whether CSPG influences the pathogenetic mechanisms of neuroimmunological diseases. We induced experimental autoimmune encephalomyelitis (EAE) in chondroitin 6-O-sulfate transferase 1-deficient (C6st1 −/− ) mice. C6ST1 is the enzyme that transfers sulfate residues to position 6 of N-acetylgalactosamine in the sugar chain of CSPG. The phenotypes of EAE in C6st1 −/− mice were more severe than those in wild-type (WT) mice were. In adoptive-transfer EAE, in which antigen-reactive T cells from WT mice were transferred to C6st1 −/− and WT mice, phenotypes were significantly more severe in C6st1 −/− than in WT mice. The recall response of antigen-reactive T cells was not significantly different among the groups. Furthermore, the number of pathogenic T cells within the CNS was also not considerably different. When EAE was induced in C6ST1 transgenic mice with C6ST1 overexpression, the mice showed considerably milder symptoms compared with those in WT mice. In conclusion, the presence of sulfate at position 6 of N-acetylgalactosamine of CSPG may influence the effecter phase of EAE to prevent the progression of pathogenesis. Thus, modification of the carbohydrate residue of CSPG may be a novel therapeutic strategy for neuroimmunological diseases such as multiple sclerosis.
Introduction
Chondroitin sulfate proteoglycans (CSPGs) are a family of glycosaminoglycans consisting of glucuronic acid, N-acetylgalactosamine and sulfate. CSPG is the main constituent of the extracellular matrix in the central nervous system (CNS) and influences neuroplasticity (Rolls et al. 2006) . For example, CSPG levels are up-regulated after CNS injury (McKeon et al. 1999; Asher et al. 2001; Jones et al. 2002) and during the course of chronic neurodegenerative disorders such as multiple sclerosis (Sobel and Ahmed 2001) and Alzheimer's disease (Inoue 2001) . CSPG attenuates regeneration in the CNS (Properzi et al. 2003; Silver and Miller 2004) by inhibiting neuronal growth (Bradbury et al. 2002; Grimpe and Silver 2002) and regulating the activation of immune components (Fitch and Silver 1997) .
For instance, CSPG inhibits axonal regeneration in spinal cord injury models and, conversely, CSPG degradation by the enzyme chondroitinase ABC promotes repair (Bradbury et al. 2002; Chau et al. 2004; Huang et al. 2006) . In general, inhibition of non-systemic neuronal projection protects the neuronal network. These reports suggest that CS moieties of CSPGs are responsible for PNN formation and control of the critical period plasticity. However, importance of sulfation pattern of CS chains in the plasticity has been overlooked in these previous studies due to the exclusive use of ChABC that degrades all CS chains, irrespective of their sulfation status. Sulfation profiles of CS chains change dramatically during brain development (Mikami and Kitagawa 2013) . Although the role of CSPG in autoimmune disease has not been analyzed in detail, some reports have indicated that CSPG promotes recovery in CNS immunopathologies such as experimental autoimmune encephalomyelitis (EAE). For example, administration of CSPG alleviates the clinical symptoms of EAE and reduces microglia activation and the number of infiltrating T cells (Zhou et al. 2010) . Furthermore, the deletion of protein tyrosine phosphatase receptor type Z as CSPG in the CNS delays recovery from paralysis associated with EAE. These results indicate that CSPG has a role in CNS recovery and might therefore be helpful in overcoming inflammation-induced neurodegenerative conditions (Harroch et al. 2002) .
Chondroitin 6-sulfotransferase (C6ST) catalyzes the transfer of sulfate to position 6 of the N-acetylgalactosamine residue of chondroitin. Sulfation that occurs mainly at the C-6 position of the internal GalNAc residue produces chondroitin 6-sulfate (C6S), whereas the C-4 sulfated form is called (C4S).
C6S is the dominant form of chondroitin in the fetal period; however, the percentage of chondroitin 4-sulfate increases during development. Sulfation patterns vary depending on organ, age, cell progression and other factors. For instance, distinctive increases in C6S are seen in the spleen, lung, bone marrow and eye, and C6S plays a role in the maintenance of naive T lymphocytes in the spleen of young mice (Uchimura et al. 2002) . Molecular cloning of human C6ST has revealed two orthologous genes, C6ST1 Uchimura et al. 1998 ) and C6ST2 (Kitagawa et al. 2000) . Expression of both isoforms in the brain is evident during development but negligible in adulthood. C6ST1 is one of the sulfotransferases involved in the biosynthesis of sulfated glycosaminoglycans; however, in vivo functional analysis of C6ST1-deficient mice shows no apparent abnormality in brain development (Uchimura et al. 2002) . In the present study, we analyzed the role of CSPG in EAE using C6ST1-deficient mice.
Materials and methods

Mice
Wild-type (WT) C57BL/6 mice were purchased from Clea Japan (Tokyo, Japan). C6ST1
−/− mice were originally obtained from Dr. Kadomatsu (Nagoya, Japan) and have been described previously. The mice had been backcrossed to the C57BL/6 background for more than five generations.
Mice were rendered deficient in the C6st1 −/− gene via embryonic stem cell technology. C6st1 −/− mice were born at approximately the expected frequency and were viable through adulthood. Brain development was normal in C6st1 −/− mice. Further analysis revealed that the number of CD62L + CD44 low T lymphocytes corresponding to naive T lymphocytes in the spleen of C6st1 −/− mice was significantly decreased, whereas that in other secondary lymphoid organs was unchanged (Uchimura et al. 2002) . Genotyping of C6ST1 −/− mice was performed with polymerase chain reaction as described elsewhere.
C6ST1 transgenic mice (C6ST1 tg ) were obtained from Dr. Kitagawa (Miyata et al. 2012) . Full-length human C6ST1 complementary DNA was amplified with reverse transcription polymerase chain reaction using a human placenta complementary DNA library and cloned into the EcoRI site of a pCAG vector, which drives transgene expression using a chicken β-actin promoter and cytomegalovirus enhancer (Niwa et al. 1991) . Plasmid DNA was injected into C57BL6 embryos, which were placed into pseudopregnant females to produce transgenic offspring. Transgenic mice were identified with Southern blot using tail DNA and were mated with C57BL6 WT mice. Mice were kept under specific pathogen-free conditions in an environmentally controlled, clean room. All experiments were conducted according to institutional ethics guidelines for animal experiments and safety guidelines for gene manipulation experiments. These mice were maintained under specific pathogen-free conditions. All mice for experiments were 8-12 weeks old.
Peptides
Myelin oligodendrocyte glycoprotein ) (single-letter amino acid code, MEVGWYRSPFSRVVHLYRNGK) was synthesized by Tore Research Institute (Tokyo, Japan). The peptides were of >90% purity, as determined by highperformance liquid chromatography (HPLC).
Induction and assessment of EAE
Mice were injected subcutaneously in both flanks with 200 µL of inoculum containing 100 µg MOG 35-55 and 0.5 mg Mycobacterium tuberculosis H37Ra (Difco Laboratories, Detroit, MI) in incomplete Freund's adjuvant. Pertussis toxin (200 ng; List Biological Laboratories Inc., Campbell, CA) was injected intravenously on days 0 and 2 after immunization. For EAE induction in the adoptive-transfer model, recipient mice were injected intravenously with encephalitogenic cells ( prepared as in Preparation of cells for EAE induction in the adoptive-transfer model section) and 200 ng of pertussis toxin. Immunized mice were examined daily and scored as follows: 0, no clinical signs; 1, limp tail; 2, partial hind leg paralysis; 3, total hind leg or partial hind and front leg paralysis; 4, total hind leg and partial front leg paralysis; 5, moribund or dead. Mice were examined daily in a blind fashion for signs of EAE.
Preparation of cells for EAE induction in the adoptive-transfer model
For preparation of MOG-specific cells to induce EAE in the adoptive-transfer model, mice were immunized with MOG/ complete Freund's adjuvant following the protocol used to induce EAE. Draining lymph nodes (LNs) were collected 10 days later, and a single-cell suspension was prepared. The cells were stimulated with 30 µg/mL MOG 35-55 in 24-well flat-bottomed plates (5 × 10 6 cells/well) in T-cell medium (RPMI media enriched with 10% fetal bovine serum, 2 mM L-glutamine, 5 × 10 -5 M 2-ME, nonessential amino acids, sodium pyruvate and penicillin/streptomycin). Recombinant mouse interleukin (IL)-12 was added at 20 ng/mL. Four days after initiation of the cultures, cells were harvested, and CD4 + cells were selected using a column (R&D, Minneapolis, MN). Ten million CD4 + cells were injected intravenously into recipient mice as described above for EAE induction.
Establishment of a MOG 35-55 -specific T-cell line
A MOG-specific T-cell line was established using cells for adoptive-transfer EAE as described above. The cells were cultured in T-cell medium with 10 ng/mL of IL-2. Half of the medium was replaced every few days. Stimulation with 30 µg/ mL MOG 35-55 was performed every 10 days with irradiated (30 Gy) splenocytes as antigen-presenting cells.
MOG 35-55 -specific T-cell proliferation assay For proliferation assays, mice were immunized with peptide/ CFA as described above, but the mice were not treated with pertussis toxin. A single-cell suspension was prepared from the draining LNs 10 days after immunization. Cells were cultured in Dulbecco's modified Eagle medium (Gibco, Grand Islands, NY) supplemented with 5 × 10 −5 M 2-mercaptoethanol, 2 mM L-glutamine, 100 U/mL of penicillin and streptomycin and 1% autologous mouse serum and seeded onto 96-well flatbottomed plates (1 × 10 6 cells/well). The cells were restimulated with peptide for 72 h at 37°C in humidified air with 5% CO 2 . To measure cellular proliferation, [ responses of LN cells to the peptide, we determined the delta (Δ)c.p.m. value for cells in each well by subtracting the background c.p.m. and then used the mean of these values to represent each mouse.
Detection of cytokines
In parallel, LN cells from immunized mice were cultured with peptide concentrations of 0, 1, 10 and 100 µg/mL. Supernatants from the cultures were harvested 48 h postactivation and tested for the presence of various cytokines. The concentrations of interferon gamma (IFN-g), IL-2, IL-4 and IL-10 in the supernatants were measured with sandwich enzyme-linked immunosorbent assay according to the manufacturer guideline (BD Biosciences, San Jose, CA). Limits of detection for IFN-g, IL-2, IL-4 and IL-10 were 195, 25, 12.5, and 50 pg/mL, respectively.
Analysis of infiltrating cells isolated from the CNS Wt and C6ST1
−/− mice were anesthetized with diethyl ether on day 9 after EAE induction. After perfusion with phosphatebuffered saline, the brain and spinal cord were removed and homogenized. After washing with phosphate-buffered saline, mononuclear cells were isolated using Percoll gradient (Amersham Biosciences, Piscataway, NJ) and counted (Miyamoto et al. 2006 ). The cells were stained with phycoerythrin-labeled anti-CD4 antibody (BD Biosciences) and analyzed with flow cytometry using a BD FACSCalibur device. As a control, naive mice were also analyzed for the infiltration of cells into the CNS using the same method.
Pathological analysis
The brain and spinal cord were removed on day 14 after the induction of EAE. Ten-micrometer-thick frozen sections were fixed with acetone and stained with hematoxylin and eosin or Luxol fast blue.
HPLC analysis
Soluble CSPG fractions from brain were prepared as described previously (Kitagawa et al. 1997) . In brief, brains from WT or C6st1 −/− mice, at pre-or postimmunization EAE, were homogenized in ice-cold PBS containing EDTA and phenylmethylsulfonyl fluoride. After centrifugation, supernatant fluids were concentrated, and then washed with Tris-HCl buffer containing sodium acetate. The protein concentration of the proteoglycan fractions was determined using the BCA protein assay kit. These fractions were first digested using chondroitin ABC lyase and evaporated to dryness.
The digests were derivatized with 2-aminobenzamide according to the manufacturer's instructions (SIGNAL™ labeling kit, Oxford GlycoSystems). The labeled disaccharides were analyzed by on an amine-bound silica PA03 column. The HPLC was performed in an LC-10AS system (Shimadzu Co., Kyoto, Japan).
Statistics
Non-parametric Mann-Whitney U tests were used to calculate significant levels for all measurements. Values of P < 0.05 were considered statistically significant.
Results
Exacerbation of EAE in C6ST1
−/− mice To examine the role of C6ST1 in the development of EAE, we first performed active immunization to establish EAE. The clinical symptoms of EAE in C6ST1 −/− mice were more severe than those in WT mice were. Statistically, a significant difference in EAE maximum score and cumulative score was found between C6ST1
−/− and WT mice (Figure 1 , Table I ). Histological comparison of the thoracic regions of the spinal cord demonstrated exacerbated monocyte infiltration and demyelination in C6ST1 −/− mice compared with WT mice (not shown). We next performed adoptive-transfer EAE. When we transferred MOG-reactive T cells from WT mice to C6ST1 −/− or WT mice, the severity of EAE in the C6ST1 −/− mice was significantly higher than that in WT mice (Figure 2 ; Table I ). These results indicate that a lack of C6S does not affect the induction phase of EAE but exhibits effects during the effector phase of EAE. Table IA . Two independent experiments are expressed as the mean EAE score. Figure 1. (B) Adoptive-transfer EAE. One million encephalitogenic CD4 + T cells from WT mice were injected intravenously into WT or C6ST1 −/− mice (recipient). The data are the same as in Figure 4 . Mean ± SEM of the following parameters is shown: maximum score of EAE (max score), incidence of paralyzed mice among sensitized rats (Incidence), summation of the clinical scores from days 0 to 35 (Cumulative score). The statistical significance of the difference was determined using ANOVA, *P < 0.05 vs. WT mice.
Chondroitin 6-O-sulfate ameliorates EAE
Spinal cord from C6ST1
−/− mice shows severe cell infiltration in comparison with it from WT ( Figure 3 ). This shows that the presence of C6ST inhibits the infiltration of pathogenic lymphocyte in EAE.
C6ST1 has no effect on the recall response of MOG-specific T cells To determine the mechanisms of C6S in T-cell activation, we examined the proliferative response and cytokine production of draining LN cells in vitro. C6ST1 −/− or WT mice were immunized with MOG . Ten days after immunization, draining LN cells were collected and cultured with MOG 35-55 peptide. As shown in Figure 4 , no significant difference was found in the proliferative responses of MOG-reactive T cells in C6ST1 −/− and WT mice. We next examined the levels of cytokines in the culture supernatant using enzyme-linked immunosorbent assay. Levels of IFN-g, IL-4, IL-10 and IL-17 in the culture supernatants of LN cells obtained from C6ST1 −/− and WT mice were similar (data not shown).
Lack of C6S has no effect on the infiltration of pathogenic T cells into the CNS
To analyze the mechanism of C6S on the infiltration of the inflammatory cells into the CNS, we isolated mononuclear cells in CNS samples obtained from each mouse on day 9 of active-immunization EAE. This period occurs just before the onset of EAE in WT mice; none of the mice exhibited EAE symptoms at that time. As shown in Figure 5 , the CD4 + cell number in the CNS samples from C6ST1 −/− mice was not significantly different from that in the samples from WT mice (14.3 ± 2.8 vs. 13.3 ± 2.6, as mean ± standard error of the mean, ×10 5 ). This result suggests that C6S has no effect on the migration of pathogenic T cells into the CNS.
Expression level of C6S in CNS during EAE
To confirm whether C6S is up-regulated in CNS, HPLC analysis was performed. Figure 6 shows that C-unit CS (C6S) did not detected in brains from C6st1 −/− mice. In WT mice, increased expression of C-unit CS did not observed in brains from EAE immunized mice in comparison with brains from naive mice. Table IB . These data are shown as mean clinical scores ± standard error of the mean (SEM). 
Amelioration of EAE in C6ST1 tg mice
Next, we analyzed whether overexpression of C6ST reduces the progression of EAE. EAE was induced in C6ST1 tg mice overexpressing C6ST1. The maximum score of C6ST1 tg mice was significantly lower than that of WT mice. The cumulative score of C6ST1 tg mice was also significantly lower than that of WT mice. In contrast, the score of C6ST1 −/− mice was significantly higher than that of WT mice (Figure 7 ; Table II ). These results suggested that C6ST1 ameliorates the pathogenesis of EAE.
Discussion
We have previously shown that the onset of EAE is delayed in mice lacking complex gangliosides owing to the lack of GM2/GD2 synthase. The carbohydrate portion of complex gangliosides may be involved in the migration of activated T lymphocytes across the blood-brain barrier (Miyamoto et al. 2008) . Thus, modification of the carbohydrate portion of the glycoconjugates may affect the pathogenetic mechanisms of EAE. In the current study, we demonstrated that CSPG is involved in the pathogenesis of EAE. Active-immunization and adoptive-transfer experiments showed that lack of C6ST1 exacerbated the disease severity of EAE in the effector phase. No difference was found in the recall response of lymphocytes to MOG in C6ST1-deficient mice compared with WT mice. Furthermore, the lack of C6ST1 did not affect the passage of activated T lymphocytes across the blood-brain barrier in EAE. Moreover, overexpression of C6ST reduced the pathogenesis of EAE. The results suggest that C6S could have a neuroprotective effect in the effector phase of EAE. Because C-unit CS (C6S) does not increase during EAE, C6S may be acting protectively regardless of the immunization.
Recently, CSPG has been implicated in several intriguing biological phenomena, such as the regulation of growth factor functions (Deepa et al. 2002) , cell division (Sugahara and Mikami 2007) and neuritogenesis (Li et al. 2007 ). In addition, a missense mutation of C6ST1 has been demonstrated to Table II . Two independent experiments are shown as the mean clinical score ± SEM. Active-immunization EAE. Each mouse was immunized with MOG peptide for the induction of EAE. The data are the same as in Figure 7 . Mean ± SEM of the following parameters is shown: maximum score of EAE (max score), incidence of paralyzed mice among sensitized rats (incidence), summation of the clinical scores from days 0 to 35 (cumulative score). The statistical significance of the difference was determined using ANOVA, *P < 0.05 vs. WT mice, # P < 0.001 vs. C6ST1 −/− mice. −/− (14.3 ± 2.8, n = 3) and naive mice (1.4 ± 0.3, n = 3). *P < 0.05
by Mann-Whitney U test. Fig. 6 . C6S is not up-regulated during the development EAE. To confirm whether C-unit CS (C6S, closed square) is up-regulated in the CNS during the development EAE, HPLC analysis was performed. The fractionation and analysis of oligosaccharides were carried out by HPLC as described in Materials and methods section. This shows that the expression level of C6S is no change during the development EAE.
Chondroitin 6-O-sulfate ameliorates EAE abolish C6ST activity almost completely and cause severe human chondrodysplasia with major involvement of the spine (Thiele et al. 2004; van Roij et al. 2008) . In a spinal cord injury model, CSPG inhibits re-innervation, and a CSPG-degrading enzyme promotes axonal regeneration (Kawano et al. 2005) . Chondroitinase ABC treatment up-regulates regeneration-associated proteins in injured neurons and promotes the regeneration of both ascending sensory projections and descending corticospinal tract axons (Bradbury et al. 2002) . Treatment with transforming growth factor-beta1 upregulates keratan sulfate and CSPG biosynthesis (Yin et al. 2009) , and it promotes the expression of C6ST1 (Properzi et al. 2005) in microglia after brain injury. CSPG3, or neurocan, is up-regulated in the periventricular white matter and cortex in the effector phase of EAE. CSPG3 is indicative of cell recruitment for repair processes and is confirmed by the presence of thin myelin sheaths in the plaques (Sajad et al. 2011 ). Thus, CSPG3 may play a crucial role in CNS regeneration in EAE.
Phosphacan is a CSPG that accelerates nerve recovery and has crucial roles in the maintenance of oligodendrocytes (Ranjan and Hudson. 1996) . Studies have shown that the administration of CSPG causes severe clinical symptoms in EAE (Rolls et al. 2006 ). Zhou et al. demonstrates that a disaccharide fraction of 6-sulfated C units reduces EAE, while 4-sulfated CS-A may actually make things worse (Zhou et al. 2010) . The variable results of these experiments indicate that a consensus has not yet been reached on the therapeutic effect of CSPG. In our study, C6S displayed a neuroprotective effect in EAE. Modification of sulfation pattern to increase C6S levels in the CNS is used as a treatment for EAE. C6S may inhibit the spread of pathogenic T cells in the CNS. Although CSPG prevents nerve regeneration in the recovery phase of the nerve injury model, CSPG may prevent disease progression in the acute phase of EAE. Thus, modification of the carbohydrate structure of CSPG could be used as a new therapeutic method for neuroimmunological diseases such as multiple sclerosis.
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